NextPlat Corp (NXPL) Stock Analysis and Metrics

NextPlat

NASDAQ: NXPL

$5.93 ▲ +0.02 (+0.42%)

At close: Jul 24, 2026 · 12:12 PM UTC

Financial Ratios

Market Cap30,182.37

P/E-1.39

P/S0.00

Div. Yield0.00

Total Debt (Qtr)846,000.00

Revenue Growth (1y) (Qtr)-29.23

Add ratio to table…

About

NextPlat Corp is a global e-commerce and healthcare services company that operates through two reportable segments: e-Commerce Operations and Healthcare Operations. Through these segments, the Company provides satellite-enabled communication products and services, global online distribution capabilities, pharmacy services, healthcare technology solutions, and data analytics services.

The Company generates revenue from product sales and recurring service subscriptions. In the e-Commerce segment, revenue comes from selling satellite phones, tracking devices, broadband terminals, and related equipment, as well as from recurring airtime subscriptions, messaging plans, and connectivity services. In the Healthcare segment, revenue is derived from dispensing prescription pharmaceuticals, compounded medications, specialty medications, medication therapy management, and data management services provided to healthcare organizations and payors. The Company serves consumers, enterprises, healthcare providers, government organizations, and other institutions across multiple geographic markets. For the year ended December 31, 2025, approximately 27% of revenue was generated by the e-Commerce segment and 73% by the healthcare segment.

The company operates through the following segments: e-Commerce Operations and Healthcare Operations.

• e-Commerce Operations provides satellite communications products, connectivity services, and related equipment to customers globally through proprietary online platforms and third-party marketplaces. This segment includes three proprietary global e-Commerce websites, approximately 25 third-party marketplace storefronts, and more than 10,000 product listings across multiple marketplaces, enabling distribution to customers in more than 165 countries. Revenue is generated from product sales and recurring service revenue such as satellite airtime subscriptions, messaging plans, and connectivity services. A significant portion of e-Commerce revenue comes from third-party marketplaces, particularly Amazon, which represented approximately 31% of total e-Commerce revenue in 2025.

• Healthcare Operations operates through a wholly owned subsidiary, Progressive Care, LLC, which includes pharmacy subsidiaries Pharmco and ClearMetrX. Pharmco provides prescription pharmaceuticals, compounded medications, anti-retroviral and other specialty medications, medication therapy management, and contracted pharmacy services for 340B covered entities and government facilities. ClearMetrX offers data management and reporting services, including pharmacy data analytics and Third-Party Administration services for 340B covered entities, to support healthcare organizations in improving patient outcomes and practice performance. The pharmacies accept most major insurance plans and provide access to co-pay assistance programs, discount and manufacturer coupons, and competitive cash payment options.

The Company competes in the mobile satellite products and services sector of the global communications industry for its e-Commerce operations, facing competition from other resellers of leading satellite networks such as Iridium, Inmarsat, Thuraya, Globalstar, and Starlink. In the Healthcare segment, it competes with national and independent retail drug stores, supermarkets, convenience stores, mail order prescription providers, discount merchandisers, membership clubs, health clinics, provider dispensaries, and internet pharmacies. Competitive strengths include a global e-commerce presence enabling 24/7/365 customer support, significant inventory stored in fulfillment centers for rapid order fulfillment, economies of scale across the supply chain, long-standing partnerships with satellite networks like Globalstar, high performance scores in pharmacy operations (Five Stars per EQuIPP® for 2025), proactive patient engagement models, and a diverse workforce with multilingual capabilities that enhance service delivery across communities.

The Company serves consumers, enterprises, healthcare providers, government organizations, military and humanitarian organizations, individual users, lone workers, and institutions across more than 165 countries. Specific customer types include recreational travelers, government and military users, corporations, emergency services, maritime, aviation, utilities, oil and gas, mining, recreation, forestry, heavy equipment, construction, and transportation sectors. In healthcare, the customer base includes patients, physicians, health systems, and payors such as health insurance plans and pharmacy benefit managers.

Investment Thesis

▲ Bull case

NextPlat is positioned to capitalize on a structural shift in the U.S. healthcare delivery model toward value-based, contract-driven pharmacy services, particularly within the 340B and long-term care segments, which represent higher-margin, recurring revenue streams less vulnerable to retail competition and pricing pressures. The company has already secured five new 340B pharmacy service agreements in Q1 FY26 alone—a single-quarter record—each with a ~90-day onboarding cycle, positioning these contracts to begin contributing meaningfully to revenue in Q3 FY26. This pipeline is not merely additive; it reflects a strategic pivot away from volatile retail prescription volume toward sticky, contract-based fulfillment where gross margins have already improved to 39% in the pharmacy business (up from ~20% YoY), driven by optimized payer mix and favorable reimbursement under the Medicare Maximum Fair Price program. The expansion of this model nationally—enabled by the newly created nationwide fulfillment partnership and the planned launch of a national e-commerce healthcare website before Q2 FY26 end—creates a scalable platform to replicate Florida-based success across all 50 states, unlocking a TAM far beyond the company’s current Florida-centric footprint. Management’s explicit intent to expand into all 50 states from its current base, combined with the quiet rollout of infrastructure for the nationwide partnership, suggests an underappreciated catalyst: the potential for rapid, asset-light geographic scaling without proportional increases in fixed costs, which could drive operating leverage and push the healthcare segment into sustained profitability well before the second half of 2026 as currently guided.
The e-commerce segment, often overlooked as a legacy satellite communications business, is undergoing a quiet but significant transformation into a high-growth, recurring-revenue engine powered by global demand for satellite-enabled IoT and government/military connectivity solutions, with over 130 countries served in Q1 FY26 and multiple multi-year contracts awarded during the quarter. This segment generated $3.2M in revenue—flat YoY but up sequentially from Q4 FY25—and benefits from stable, non-discretionary demand in enterprise and government markets, which are less sensitive to macroeconomic fluctuations than retail healthcare. The recent growth in satellite-enabled IoT offerings from partners like Iridium and Globalstar has driven IoT sales and recurring revenue to record highs, creating a sticky, annuity-like revenue stream with high retention and low customer acquisition costs. Crucially, this segment requires minimal capital expenditure to scale, operates with inherently high gross margins (implied by its contribution to consolidated 35% gross margin despite healthcare’s lower historical margins), and provides a reliable cash flow engine that can fund healthcare expansion initiatives without dilutive financing. The market is underestimating the strategic value of this segment as a counter-cyclical buffer and internal funding source for healthcare growth—particularly as the company prepares to launch its new e-commerce healthcare website featuring GLP-1s and OTC products, which could cross-sell to existing satellite customers and create a bundled digital health-commerce platform with far higher LTV than either business alone.
NextPlat’s balance sheet strength and newly established ATM equity program represent an underappreciated financial flexibility that could enable accretive strategic moves—such as joint ventures or tuck-in acquisitions in high-growth verticals like GLP-1 distribution or long-term care pharmacy tech—that management has hinted at but not yet disclosed. With $11M in cash, $14M in working capital, and no meaningful debt, the company possesses a rare combination of liquidity and low leverage among small-cap healthcare turnarounds, allowing it to pursue opportunistic M&A without jeopardizing financial stability. The ATM program with H.C. Wainwright, while currently unused, provides a low-cost, on-demand capital source that could be deployed swiftly if attractive targets emerge—especially in fragmented markets where scale confers pricing power and operational efficiencies. Management’s repeated emphasis on evaluating strategic opportunities, combined with their disciplined expense control and focus on high-quality revenue, suggests they are waiting for the right inflection point—likely post-Q3 FY26 when the 340B contract onboarding cycle completes and national e-commerce healthcare site launches—to deploy capital. The market is pricing NXPL as a pure turnaround play, but the combination of improving operational metrics, a scalable national healthcare platform, a resilient e-commerce cash cow, and dry powder for strategic growth creates a compelling optionality narrative that is not reflected in today’s valuation.

NextPlat is positioned to capitalize on a structural shift in the U.S. healthcare delivery model toward value-based, contract-driven pharmacy services, particularly within the 340B and long-term care segments, which represent higher-margin, recurring revenue streams less vulnerable to retail competition and pricing pressures. The company has already secured five new 340B pharmacy service agreements in Q1 FY26 alone—a single-quarter record—each with a ~90-day onboarding cycle, positioning these contracts to begin contributing meaningfully to revenue in Q3 FY26. This pipeline is not merely additive; it reflects a strategic pivot away from volatile retail prescription volume toward sticky, contract-based fulfillment where gross margins have already improved to 39% in the pharmacy business (up from ~20% YoY), driven by optimized payer mix and favorable reimbursement under the Medicare Maximum Fair Price program. The expansion of this model nationally—enabled by the newly created nationwide fulfillment partnership and the planned launch of a national e-commerce healthcare website before Q2 FY26 end—creates a scalable platform to replicate Florida-based success across all 50 states, unlocking a TAM far beyond the company’s current Florida-centric footprint. Management’s explicit intent to expand into all 50 states from its current base, combined with the quiet rollout of infrastructure for the nationwide partnership, suggests an underappreciated catalyst: the potential for rapid, asset-light geographic scaling without proportional increases in fixed costs, which could drive operating leverage and push the healthcare segment into sustained profitability well before the second half of 2026 as currently guided.
The e-commerce segment, often overlooked as a legacy satellite communications business, is undergoing a quiet but significant transformation into a high-growth, recurring-revenue engine powered by global demand for satellite-enabled IoT and government/military connectivity solutions, with over 130 countries served in Q1 FY26 and multiple multi-year contracts awarded during the quarter. This segment generated $3.2M in revenue—flat YoY but up sequentially from Q4 FY25—and benefits from stable, non-discretionary demand in enterprise and government markets, which are less sensitive to macroeconomic fluctuations than retail healthcare. The recent growth in satellite-enabled IoT offerings from partners like Iridium and Globalstar has driven IoT sales and recurring revenue to record highs, creating a sticky, annuity-like revenue stream with high retention and low customer acquisition costs. Crucially, this segment requires minimal capital expenditure to scale, operates with inherently high gross margins (implied by its contribution to consolidated 35% gross margin despite healthcare’s lower historical margins), and provides a reliable cash flow engine that can fund healthcare expansion initiatives without dilutive financing. The market is underestimating the strategic value of this segment as a counter-cyclical buffer and internal funding source for healthcare growth—particularly as the company prepares to launch its new e-commerce healthcare website featuring GLP-1s and OTC products, which could cross-sell to existing satellite customers and create a bundled digital health-commerce platform with far higher LTV than either business alone.
NextPlat’s balance sheet strength and newly established ATM equity program represent an underappreciated financial flexibility that could enable accretive strategic moves—such as joint ventures or tuck-in acquisitions in high-growth verticals like GLP-1 distribution or long-term care pharmacy tech—that management has hinted at but not yet disclosed. With $11M in cash, $14M in working capital, and no meaningful debt, the company possesses a rare combination of liquidity and low leverage among small-cap healthcare turnarounds, allowing it to pursue opportunistic M&A without jeopardizing financial stability. The ATM program with H.C. Wainwright, while currently unused, provides a low-cost, on-demand capital source that could be deployed swiftly if attractive targets emerge—especially in fragmented markets where scale confers pricing power and operational efficiencies. Management’s repeated emphasis on evaluating strategic opportunities, combined with their disciplined expense control and focus on high-quality revenue, suggests they are waiting for the right inflection point—likely post-Q3 FY26 when the 340B contract onboarding cycle completes and national e-commerce healthcare site launches—to deploy capital. The market is pricing NXPL as a pure turnaround play, but the combination of improving operational metrics, a scalable national healthcare platform, a resilient e-commerce cash cow, and dry powder for strategic growth creates a compelling optionality narrative that is not reflected in today’s valuation.

▼ Bear case

Despite reported margin improvements, NextPlat’s healthcare segment remains fundamentally challenged by declining retail prescription volume and an overreliance on a narrow set of high-margin contract services that may not be scalable or sustainable at the pace implied by management, creating a significant risk of revenue stagnation or decline even as gross margins improve. While healthcare revenue reached ~$7M in Q1 FY26 (down from ~$10M in Q4 FY25 and ~$14M YoY), the company’s optimism hinges on five new 340B contracts that require ~90 days to onboard—meaning their full impact may not be felt until Q4 FY26, leaving a potential revenue gap in Q2–Q3 FY26 if retail erosion continues unabated. The company admitted that retail prescription volume remains below prior year levels and only stabilized “further” during the quarter, signaling persistent weakness in its traditional pharmacy footprint, which still constitutes a material portion of its operations. Moreover, the 39% pharmacy gross margin, while impressive, is heavily influenced by the one-time benefit of the Medicare Maximum Fair Price program and a favorable payer mix shift that may not be repeatable or sustainable as competitors adapt or federal pricing pressures intensify. The shift toward 340B and contract services, though higher margin, introduces new execution risks: longer sales cycles, dependency on third-party facility onboarding, and vulnerability to changes in federal 340B program rules or state-level long-term care reimbursement policies—none of which were addressed in the Q&A. Without clear evidence of accelerating new contract wins beyond the five cited, or a credible plan to offset ongoing retail declines, the margin expansion may be a temporary reprieve rather than a durable foundation for growth.
The e-commerce segment’s strength in satellite connectivity and IoT is being overstated as a durable competitive advantage, as it faces increasing commoditization, intense competition from larger players like Iridium and Globalstar (who now offer direct-to-consumer and enterprise solutions), and potential erosion of recurring airtime revenue due to technological shifts toward terrestrial 5G and LEO satellite constellations that may reduce reliance on legacy satellite hardware. While the company cited “record highs” in IoT sales and recurring revenue, it provided no breakdown of gross margins, customer concentration, or contract renewal rates for this segment—raising concerns that the growth may be driven by low-margin hardware resale or one-time government orders rather than sticky, high-margin services. The claim of serving customers in over 130 countries sounds impressive but masks potential fragmentation and low average revenue per user (ARPU), especially if sales are heavily weighted toward low-value consumer gear rather than enterprise or government contracts. Furthermore, the planned launch of a national e-commerce healthcare website featuring GLP-1s and OTC products introduces significant regulatory, compliance, and inventory risks—particularly around controlled substances like GLP-1s—that management did not quantify or mitigate in their discussion, suggesting the initiative may be more aspirational than actionable in the near term. The segment’s ability to fund healthcare expansion is unproven; if IoT revenue is volatile or margin-thin, it may not generate the predictable cash flow implied by management, leaving the company dependent on external capital for growth.
NextPlat’s turnaround narrative is dangerously reliant on continued expense discipline and operating leverage, yet the company shows no signs of reversing its long-term trend of declining top-line revenue—a critical flaw that could undermine profitability gains even if margins hold. Total net revenues fell to ~$10M in Q1 FY26 from ~$14M YoY and ~$13M in Q4 FY25, reflecting a persistent inability to grow the top line despite cost-cutting measures. While management attributes this to “operational restructuring and evolving reimbursement dynamics,” the lack of any meaningful sequential revenue growth (Q1 FY26 revenue was lower than Q4 FY25) suggests the business is still in contraction mode, not recovery. The healthcare segment’s revenue decline—despite margin improvements—indicates that the company is selling fewer prescriptions at higher margins, a strategy that has natural limits and cannot compensate indefinitely for volume loss. Operating expenses were reduced to ~$4.5M, but this came from salary and wage cuts (~$2.4M vs. ~$2.7M YoY), raising concerns about talent retention, institutional knowledge loss, and diminished capacity to support growth initiatives like national expansion or new product launches. The ATM program, while presented as a flexibility tool, signals that management anticipates needing external capital to fund growth—yet they have no concrete plans for its use, implying uncertainty about internal cash generation. If revenue continues to decline or stagnate, the company may be forced to dilute shareholders via the ATM just to maintain operations, turning a purported strength into a significant overhang. The market may be ignoring the fact that true turnarounds require both margin expansion *and* revenue stabilization or growth—NXPL has achieved neither on the top line.

Despite reported margin improvements, NextPlat’s healthcare segment remains fundamentally challenged by declining retail prescription volume and an overreliance on a narrow set of high-margin contract services that may not be scalable or sustainable at the pace implied by management, creating a significant risk of revenue stagnation or decline even as gross margins improve. While healthcare revenue reached ~$7M in Q1 FY26 (down from ~$10M in Q4 FY25 and ~$14M YoY), the company’s optimism hinges on five new 340B contracts that require ~90 days to onboard—meaning their full impact may not be felt until Q4 FY26, leaving a potential revenue gap in Q2–Q3 FY26 if retail erosion continues unabated. The company admitted that retail prescription volume remains below prior year levels and only stabilized “further” during the quarter, signaling persistent weakness in its traditional pharmacy footprint, which still constitutes a material portion of its operations. Moreover, the 39% pharmacy gross margin, while impressive, is heavily influenced by the one-time benefit of the Medicare Maximum Fair Price program and a favorable payer mix shift that may not be repeatable or sustainable as competitors adapt or federal pricing pressures intensify. The shift toward 340B and contract services, though higher margin, introduces new execution risks: longer sales cycles, dependency on third-party facility onboarding, and vulnerability to changes in federal 340B program rules or state-level long-term care reimbursement policies—none of which were addressed in the Q&A. Without clear evidence of accelerating new contract wins beyond the five cited, or a credible plan to offset ongoing retail declines, the margin expansion may be a temporary reprieve rather than a durable foundation for growth.
The e-commerce segment’s strength in satellite connectivity and IoT is being overstated as a durable competitive advantage, as it faces increasing commoditization, intense competition from larger players like Iridium and Globalstar (who now offer direct-to-consumer and enterprise solutions), and potential erosion of recurring airtime revenue due to technological shifts toward terrestrial 5G and LEO satellite constellations that may reduce reliance on legacy satellite hardware. While the company cited “record highs” in IoT sales and recurring revenue, it provided no breakdown of gross margins, customer concentration, or contract renewal rates for this segment—raising concerns that the growth may be driven by low-margin hardware resale or one-time government orders rather than sticky, high-margin services. The claim of serving customers in over 130 countries sounds impressive but masks potential fragmentation and low average revenue per user (ARPU), especially if sales are heavily weighted toward low-value consumer gear rather than enterprise or government contracts. Furthermore, the planned launch of a national e-commerce healthcare website featuring GLP-1s and OTC products introduces significant regulatory, compliance, and inventory risks—particularly around controlled substances like GLP-1s—that management did not quantify or mitigate in their discussion, suggesting the initiative may be more aspirational than actionable in the near term. The segment’s ability to fund healthcare expansion is unproven; if IoT revenue is volatile or margin-thin, it may not generate the predictable cash flow implied by management, leaving the company dependent on external capital for growth.
NextPlat’s turnaround narrative is dangerously reliant on continued expense discipline and operating leverage, yet the company shows no signs of reversing its long-term trend of declining top-line revenue—a critical flaw that could undermine profitability gains even if margins hold. Total net revenues fell to ~$10M in Q1 FY26 from ~$14M YoY and ~$13M in Q4 FY25, reflecting a persistent inability to grow the top line despite cost-cutting measures. While management attributes this to “operational restructuring and evolving reimbursement dynamics,” the lack of any meaningful sequential revenue growth (Q1 FY26 revenue was lower than Q4 FY25) suggests the business is still in contraction mode, not recovery. The healthcare segment’s revenue decline—despite margin improvements—indicates that the company is selling fewer prescriptions at higher margins, a strategy that has natural limits and cannot compensate indefinitely for volume loss. Operating expenses were reduced to ~$4.5M, but this came from salary and wage cuts (~$2.4M vs. ~$2.7M YoY), raising concerns about talent retention, institutional knowledge loss, and diminished capacity to support growth initiatives like national expansion or new product launches. The ATM program, while presented as a flexibility tool, signals that management anticipates needing external capital to fund growth—yet they have no concrete plans for its use, implying uncertainty about internal cash generation. If revenue continues to decline or stagnate, the company may be forced to dilute shareholders via the ATM just to maintain operations, turning a purported strength into a significant overhang. The market may be ignoring the fact that true turnarounds require both margin expansion *and* revenue stabilization or growth—NXPL has achieved neither on the top line.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Software - Application

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SAP	Sap Se	208.91 Bn	20.22	4.86	7.05 Bn
2	YMM	Full Truck Alliance Co. Ltd.	188.77 Bn	322.09	-	0.00 Bn
3	SHOP	Shopify Inc.	145.98 Bn	109.59	11.80	-
4	UBER	Uber Technologies, Inc	141.48 Bn	16.32	2.64	10.51 Bn
5	CRM	Salesforce, Inc.	128.51 Bn	16.95	3.00	39.28 Bn
6	NOW	ServiceNow, Inc.	98.38 Bn	54.17	7.05	7.52 Bn
7	ADP	Automatic Data Processing Inc	97.56 Bn	22.45	4.52	3.98 Bn
8	SNOW	Snowflake Inc.	91.55 Bn	-76.63	18.19	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password